{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:05:16Z","timestamp":1790024716326,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:24:05Z","timestamp":1790022245000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Initiation d\u2019une r\u00e9union de concertation pluridisciplinaire nationale de recours en n\u00e9phro-oncologie\u00a0: retour d\u2019exp\u00e9rience des deux premi\u00e8res ann\u00e9es"],"prefix":"10.1016","author":[{"given":"Mihaela","family":"Ambroci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Fenioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Durrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Sakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dil","family":"Sahali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Kempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bulcan.2026.07.003_bib0170","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1053\/j.ackd.2021.10.007","article-title":"Chronic kidney disease in cancer survivors","volume":"28","author":"Lee","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.bulcan.2026.07.003_bib0175","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.003_bib0180","first-page":"2356","article-title":"Association between chronic kidney disease and cancer including the mortality of cancer patients: national health and nutrition examination survey 1999-2014","volume":"14","author":"Guo","year":"2022","journal-title":"Am J Transl Res"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.003_bib0185","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1200\/JCO.19.02138","article-title":"Improving cancer care for patients with chronic kidney disease","volume":"38","author":"Sprangers","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.bulcan.2026.07.003_bib0190","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.2018.7260","article-title":"Representation of patients with chronic kidney disease in trials of cancer therapy","volume":"319","author":"Kitchlu","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.003_bib0195","first-page":"129","article-title":"Development and organization of onco-nephrology in France, comment on \u201cThe path toward the creation of the American Society of Onco-Nephrology (ASON)\u201d","volume":"6","author":"Delaye","year":"2022","journal-title":"J Onconephrol"},{"issue":"7\u20138","key":"10.1016\/j.bulcan.2026.07.003_bib0200","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bulcan.2023.01.018","article-title":"Management of cancer treatments in hemodialysis patients","volume":"111","author":"Matte","year":"2024","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.003_bib0205","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bulcan.2024.11.001","article-title":"Insuffisance r\u00e9nale aigu\u00eb chez les patients trait\u00e9s par inhibiteur du check-point immunitaire-recommandations communes FITC\/SFNDT","volume":"112","author":"Gueutin","year":"2025","journal-title":"Bull Cancer"},{"issue":"1\u20132","key":"10.1016\/j.bulcan.2026.07.003_bib0210","first-page":"3","article-title":"The path toward the creation of the American Society of Onco-Nephrology (ASON)","volume":"6","author":"Rashidi","year":"2022","journal-title":"J Onconephrol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.003_bib0215","first-page":"129","article-title":"Development and organization of onco-nephrology in France, comment on \u201cThe path toward the creation of the American Society of Onco-Nephrology (ASON)\u201d","volume":"6","author":"Delaye","year":"2022","journal-title":"J Onconephrol"},{"key":"10.1016\/j.bulcan.2026.07.003_bib0220","unstructured":"Association GRIFON https:\/\/assogrifon.webnode.fr\/."},{"key":"10.1016\/j.bulcan.2026.07.003_bib0225","unstructured":"DU de n\u00e9phro-oncologie https:\/\/www.u-pec.fr\/fr\/formation\/du-de-nephro-oncologie."},{"key":"10.1016\/j.bulcan.2026.07.003_bib0230","unstructured":"RCP n\u00e9phro-oncologie https:\/\/www.sfndt.org\/node\/1571."},{"issue":"4","key":"10.1016\/j.bulcan.2026.07.003_bib0235","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.bulcan.2026.07.003_bib0240","doi-asserted-by":"crossref","first-page":"e003467","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2026.07.003_bib0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejca.2020.08.008","article-title":"Acute tubular necrosis after selective FGFR tyrosine kinase inhibitor therapy","volume":"139","author":"Moktefi","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.07.003_bib0250","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/ki.2013.344","article-title":"Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy","volume":"85","author":"Izzedine","year":"2014","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.bulcan.2026.07.003_bib0255","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","article-title":"Inhibition of the VEGF signalling pathway and glomerular disorders","volume":"30","author":"Ollero","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2026.07.003_bib0260","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2215\/CJN.0000000000000395","article-title":"Pharmacology of tyrosine kinase inhibitors: implications for patients with kidney diseases","volume":"19","author":"Hulin","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.003_bib0265","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1053\/j.ajkd.2016.09.026","article-title":"Nephrotic syndrome in small cell lung cancer and induction of C-mip in podocytes","volume":"69","author":"Bouatou","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.bulcan.2026.07.003_bib0270","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10637-020-01039-5","article-title":"Nephrotoxicity in patients with solid tumors treated with anti-PD-1\/PD-L1\u00a0monoclonal antibodies: a systematic review and meta-analysis","volume":"39","author":"Li","year":"2021","journal-title":"Invest New Drugs"},{"issue":"8","key":"10.1016\/j.bulcan.2026.07.003_bib0275","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.07.003_bib0280","doi-asserted-by":"crossref","first-page":"e058396","DOI":"10.1136\/bmjopen-2021-058396","article-title":"Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb\/IV CheckMate 920\u00a0trial","volume":"12","author":"George","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.003_bib0285","doi-asserted-by":"crossref","first-page":"e003844","DOI":"10.1136\/jitc-2021-003844","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b\/4\u00a0CheckMate 920\u00a0trial","volume":"10","author":"Tykodi","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2026.07.003_bib0290","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.bulcan.2026.07.003_bib0295","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1200\/JCO.2020.38.5_suppl.91","article-title":"Incidence and prediction of checkpoint inhibitor immune-related nephrotoxicity","volume":"38","author":"Sorah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2026.07.003_bib0300","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.07.003_bib0305","doi-asserted-by":"crossref","first-page":"e000144","DOI":"10.1136\/jitc-2019-000144","article-title":"Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma","volume":"8","author":"Abou Alaiwi","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.bulcan.2026.07.003_bib0310","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.07.003_bib0315","doi-asserted-by":"crossref","first-page":"964335","DOI":"10.3389\/fmed.2022.964335","article-title":"The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity","volume":"9","author":"Moss","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.bulcan.2026.07.003_bib0320","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600384X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512600384X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:24:11Z","timestamp":1790022251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512600384X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S000745512600384X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Initiation d\u2019une r\u00e9union de concertation pluridisciplinaire nationale de recours en n\u00e9phro-oncologie\u00a0: retour d\u2019exp\u00e9rience des deux premi\u00e8res ann\u00e9es","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}